Business
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results Canada NewsWire ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n\n\n Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n VICTORIA, BC\n \n\n ,\n \n\n March 20, 2025\n \n\n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.\n \n\n\n\n\n\n\n\n\n \"During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase\n \n 1b\n \n /2a RESOLVE trial for EP-104GI as a potential treatment for eosinophilic esophagitis,\" said Dr.\n \n James Helliwell\n \n , Chief Executive Officer of Eupraxia. \"The results from the first six cohorts of the trial show that precise, localized delivery of EP-104GI at higher doses is leading to further improvements in tissue health and symptom reduction outcomes. In addition, during the fourth quarter, we raised\n \n C$44.5 million\n \n , significantly strengthening our balance sheet and ensuring the Company is well-funded into the second half of 2026.\"\n \n\n\n Recent Operational and Financial Highlights\n \n\n\n\n On\n \n October 2, 2024\n \n , the Company announced the appointment of Dr.\n \n Amanda Malone\n \n as the Chief Operating and Scientific Officer of the Company.\n \n\n On\n \n October 10, 2024\n \n , the Company announced a poster presentation at the United European Gastroenterology Week 2024 featuring data from cohorts one through four of Eupraxia's ongoing RESOLVE trial in EoE.\n \n\n On\n \n October 15, 2024\n \n , the Company announced that Phase\n \n 2b\n \n data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis was published in leading peer reviewed medical journal\n \n The Lancet Rheumatology\n \n .\n \n\n On\n \n October 28, 2024\n \n...